Condition: T-Cell Non-Hodgkin Lymphoma · T-cell Lymphoma (PTCL and CTCL) · Sponsor: Beijing GoBroad Hospital
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
This description comes directly from the study's public registry record.
Haiyang LU, Ph.D · 86+ 18221015770 · lhy13062@rjh.com.cn
Always discuss trial participation with your own doctor first.
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, China | Recruiting |
| Shanghai Liquan Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07022964